Understanding and regulating autoimmune disease through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) family transcription factor, v-rel reticuloendotheliosis viral oncogene homolog B (RelB).

该方案与国家研究重点：促进和保持良好健康十分一致。类风湿性关节炎和1型糖尿病影响了超过1%的澳大利亚人口。它们是无法治愈的，因此残疾和治疗的需求会持续到老年，预期寿命会缩短。该项目侧重于更有效和更安全的治疗，以及未来疾病的预防，通过免疫疗法。这将给澳大利亚带来社会和经济效益。这项研究将促进澳大利亚在免疫学领域的智力领导地位，提供研究培训和就业机会，并将导致基础科学家、临床医生和工业界之间的紧密合作。

This program is well-aligned with the national research priority: Promoting and Maintaining Good Health. The disabling conditions rheumatoid arthritis and type 1 diabetes affect over 1% of Australia's population. They are incurable, so disability and the need for treatment persist into old age and life expectancy is reduced. The program focuses on more effective and safer treatment, and future disease prevention, with immune therapy. This will have social and economic benefits to Australia. The research will advance Australia's intellectual leadership in Immunology, providing research training and career opportunities, and will lead to strong collaborations between basic scientists, clinicians and industry.